Prospective, Multi-centre, Randomized, Parallel Comparison to Evaluate the Safety and Efficacy of the Abluminal Sirolimus Coated Bio-engineered Stent (COMBO Stent) in Association With Short-term Single Antiplatelet Therapy in Patients With Coronary Artery Disease With an Indication for Chronic Oral Anticoagulant Therapy as Compared to a Guidelines-based Strategy

Trial Profile

Prospective, Multi-centre, Randomized, Parallel Comparison to Evaluate the Safety and Efficacy of the Abluminal Sirolimus Coated Bio-engineered Stent (COMBO Stent) in Association With Short-term Single Antiplatelet Therapy in Patients With Coronary Artery Disease With an Indication for Chronic Oral Anticoagulant Therapy as Compared to a Guidelines-based Strategy

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Anti-CD34 monoclonal antibody/sirolimus (Primary) ; Clopidogrel
  • Indications Coronary artery disease; Myocardial infarction; Unstable angina pectoris
  • Focus Adverse reactions
  • Acronyms COSTA
  • Most Recent Events

    • 17 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 06 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top